Nezodia (Linagliptin)

Linagliptin, the active ingredient in Nezodia, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of blood glucose levels in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

GNH USA supplies Nezodia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and regulatory compliance, and on-time delivery to meet global demand across multiple continents.

Nezodia (linagliptin) is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise. - Adjunct to metformin therapy: provides additional glucose lowering in patients inadequately controlled on metformin alone. - Monotherapy in metformin-intolerant patients: offers an alternative oral option for glycemic management.

Linagliptin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Upper respiratory tract infection: mild cough or nasal congestion. - Headache: transient mild to moderate pain. - Nasopharyngitis: inflammation of the nasal passages and throat. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Hepatic enzyme elevation: increased ALT or AST levels.

When prescribing Nezodia, clinicians should consider several safety and handling precautions. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic disease: use with caution and monitor liver enzymes. - Cardiovascular risk: evaluate patient history of heart disease. - Concomitant sulfonylureas: increased risk of hypoglycaemia; adjust dose if needed. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin exposure. - Combination with insulin or sulfonylureas: can increase risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., thiazides): may enhance hypoglycaemic effect. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Anticoagulants (e.g., warfarin): observe INR for potential changes.